38 results on '"Taschner-Mandl, Sabine"'
Search Results
2. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
- Author
-
Pucci, Perla, Lee, Liam C., Han, Miaojun, Matthews, Jamie D., Jahangiri, Leila, Schlederer, Michaela, Manners, Eleanor, Sorby-Adams, Annabel, Kaggie, Joshua, Trigg, Ricky M., Steel, Christopher, Hare, Lucy, James, Emily R., Prokoph, Nina, Ducray, Stephen P., Merkel, Olaf, Rifatbegovic, Firkret, Luo, Ji, Taschner-Mandl, Sabine, Kenner, Lukas, Burke, G. A. Amos, and Turner, Suzanne D.
- Published
- 2024
- Full Text
- View/download PDF
3. Comparative transcriptomics coupled to developmental grading via transgenic zebrafish reporter strains identifies conserved features in neutrophil maturation
- Author
-
Kirchberger, Stefanie, Shoeb, Mohamed R., Lazic, Daria, Wenninger-Weinzierl, Andrea, Fischer, Kristin, Shaw, Lisa E., Nogueira, Filomena, Rifatbegovic, Fikret, Bozsaky, Eva, Ladenstein, Ruth, Bodenmiller, Bernd, Lion, Thomas, Traver, David, Farlik, Matthias, Schöfer, Christian, Taschner-Mandl, Sabine, Halbritter, Florian, and Distel, Martin
- Published
- 2024
- Full Text
- View/download PDF
4. The evolutionary dynamics of extrachromosomal DNA in human cancers.
- Author
-
Lange, Joshua, Rose, John, Chen, Celine, Pichugin, Yuriy, Xie, Liangqi, Tang, Jun, Hung, King, Yost, Kathryn, Shi, Quanming, Erb, Marcella, Rajkumar, Utkrisht, Wu, Sihan, Taschner-Mandl, Sabine, Bernkopf, Marie, Swanton, Charles, Liu, Zhe, Huang, Weini, Chang, Howard, Bafna, Vineet, Henssen, Anton, Werner, Benjamin, and Mischel, Paul
- Subjects
Biological Evolution ,DNA ,Extrachromosomal Inheritance ,Humans ,Neoplasms ,Oncogenes - Abstract
Oncogene amplification on extrachromosomal DNA (ecDNA) is a common event, driving aggressive tumor growth, drug resistance and shorter survival. Currently, the impact of nonchromosomal oncogene inheritance-random identity by descent-is poorly understood. Also unclear is the impact of ecDNA on somatic variation and selection. Here integrating theoretical models of random segregation, unbiased image analysis, CRISPR-based ecDNA tagging with live-cell imaging and CRISPR-C, we demonstrate that random ecDNA inheritance results in extensive intratumoral ecDNA copy number heterogeneity and rapid adaptation to metabolic stress and targeted treatment. Observed ecDNAs benefit host cell survival or growth and can change within a single cell cycle. ecDNA inheritance can predict, a priori, some of the aggressive features of ecDNA-containing cancers. These properties are facilitated by the ability of ecDNA to rapidly adapt genomes in a way that is not possible through chromosomal oncogene amplification. These results show how the nonchromosomal random inheritance pattern of ecDNA contributes to poor outcomes for patients with cancer.
- Published
- 2022
5. Twinning to reduce research and innovation inequalities in paediatric solid tumours across Europe
- Author
-
Rascon, Jelena, Blackute, Renata, Cerkauskiene, Alma, Taschner-Mandl, Sabine, Andrade, Nuno, Planinic, Adriana, Rutkowski, Stefan, Schuller, Ulrich, Nysom, Karsten, Tuckuviene, Ruta, Brok, Jesper, Schmiegelow, Kjeld, van den Heuvel-Eibrink, Marry M., van der Perk, M.E. Madeleine, Haupt, Riccardo, Muraca, Monica, Saraceno, Davide, Geoerger, Birgit, Manuzi, Giorgia, and Ladenstein, Ruth
- Published
- 2024
- Full Text
- View/download PDF
6. Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis
- Author
-
Fetahu, Irfete S., Esser-Skala, Wolfgang, Dnyansagar, Rohit, Sindelar, Samuel, Rifatbegovic, Fikret, Bileck, Andrea, Skos, Lukas, Bozsaky, Eva, Lazic, Daria, Shaw, Lisa, Tötzl, Marcus, Tarlungeanu, Dora, Bernkopf, Marie, Rados, Magdalena, Weninger, Wolfgang, Tomazou, Eleni M., Bock, Christoph, Gerner, Christopher, Ladenstein, Ruth, Farlik, Matthias, Fortelny, Nikolaus, and Taschner-Mandl, Sabine
- Published
- 2023
- Full Text
- View/download PDF
7. The molecular basis of tumor metastasis and current approaches to decode targeted migration-promoting events in pediatric neuroblastoma
- Author
-
Corallo, Diana, Dalla Vecchia, Marco, Lazic, Daria, Taschner-Mandl, Sabine, Biffi, Alessandra, and Aveic, Sanja
- Published
- 2023
- Full Text
- View/download PDF
8. Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
- Author
-
Schriegel, Felix, Taschner-Mandl, Sabine, Bernkopf, Marie, Grunwald, Uwe, Siebert, Nikolai, Ambros, Peter F., Ambros, Inge, Lode, Holger N., Henze, Guenter, and Ehlert, Karoline
- Published
- 2022
- Full Text
- View/download PDF
9. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
- Author
-
Martinez-Monleon, Angela, Kryh Öberg, Hanna, Gaarder, Jennie, Berbegall, Ana P., Javanmardi, Niloufar, Djos, Anna, Ussowicz, Marek, Taschner-Mandl, Sabine, Ambros, Inge M., Øra, Ingrid, Sandstedt, Bengt, Beiske, Klaus, Ladenstein, Ruth, Noguera, Rosa, Ambros, Peter F., Gordon Murkes, Lena, Ljungman, Gustaf, Kogner, Per, Fransson, Susanne, and Martinsson, Tommy
- Published
- 2022
- Full Text
- View/download PDF
10. Neuroblastoma and the epigenome
- Author
-
Fetahu, Irfete S. and Taschner-Mandl, Sabine
- Published
- 2021
- Full Text
- View/download PDF
11. Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8
- Author
-
Weiss, Tamara, Taschner-Mandl, Sabine, Janker, Lukas, Bileck, Andrea, Rifatbegovic, Fikret, Kromp, Florian, Sorger, Helena, Kauer, Maximilian O., Frech, Christian, Windhager, Reinhard, Gerner, Christopher, Ambros, Peter F., and Ambros, Inge M.
- Published
- 2021
- Full Text
- View/download PDF
12. Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
- Author
-
Hartlieb, Sabine A., Sieverling, Lina, Nadler-Holly, Michal, Ziehm, Matthias, Toprak, Umut H., Herrmann, Carl, Ishaque, Naveed, Okonechnikov, Konstantin, Gartlgruber, Moritz, Park, Young-Gyu, Wecht, Elisa Maria, Savelyeva, Larissa, Henrich, Kai-Oliver, Rosswog, Carolina, Fischer, Matthias, Hero, Barbara, Jones, David T. W., Pfaff, Elke, Witt, Olaf, Pfister, Stefan M., Volckmann, Richard, Koster, Jan, Kiesel, Katharina, Rippe, Karsten, Taschner-Mandl, Sabine, Ambros, Peter, Brors, Benedikt, Selbach, Matthias, Feuerbach, Lars, and Westermann, Frank
- Published
- 2021
- Full Text
- View/download PDF
13. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
- Author
-
Peneder, Peter, Stütz, Adrian M., Surdez, Didier, Krumbholz, Manuela, Semper, Sabine, Chicard, Mathieu, Sheffield, Nathan C., Pierron, Gaelle, Lapouble, Eve, Tötzl, Marcus, Ergüner, Bekir, Barreca, Daniele, Rendeiro, André F., Agaimy, Abbas, Boztug, Heidrun, Engstler, Gernot, Dworzak, Michael, Bernkopf, Marie, Taschner-Mandl, Sabine, Ambros, Inge M., Myklebost, Ola, Marec-Bérard, Perrine, Burchill, Susan Ann, Brennan, Bernadette, Strauss, Sandra J., Whelan, Jeremy, Schleiermacher, Gudrun, Schaefer, Christiane, Dirksen, Uta, Hutter, Caroline, Boye, Kjetil, Ambros, Peter F., Delattre, Olivier, Metzler, Markus, Bock, Christoph, and Tomazou, Eleni M.
- Published
- 2021
- Full Text
- View/download PDF
14. An annotated fluorescence image dataset for training nuclear segmentation methods
- Author
-
Kromp, Florian, Bozsaky, Eva, Rifatbegovic, Fikret, Fischer, Lukas, Ambros, Magdalena, Berneder, Maria, Weiss, Tamara, Lazic, Daria, Dörr, Wolfgang, Hanbury, Allan, Beiske, Klaus, Ambros, Peter F., Ambros, Inge M., and Taschner-Mandl, Sabine
- Published
- 2020
- Full Text
- View/download PDF
15. Evaluation of inflammation-related signaling events covering phosphorylation and nuclear translocation of proteins based on mass spectrometry data
- Author
-
Bileck, Andrea, Mayer, Rupert L., Kreutz, Dominique, Weiss, Tamara, Taschner-Mandl, Sabine, Meier, Samuel M., Slany, Astrid, and Gerner, Christopher
- Published
- 2017
- Full Text
- View/download PDF
16. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
- Author
-
Rifatbegovic, Fikret, Frech, Christian, Abbasi, M. Reza, Taschner‐Mandl, Sabine, Weiss, Tamara, Schmidt, Wolfgang M., Schmidt, Iris, Ladenstein, Ruth, Ambros, Inge M., and Ambros, Peter F.
- Published
- 2018
- Full Text
- View/download PDF
17. Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma.
- Author
-
Italia, Matteo, Wertheim, Kenneth Y., Taschner-Mandl, Sabine, Walker, Dawn, and Dercole, Fabio
- Subjects
TUMOR treatment ,THERAPEUTIC use of antineoplastic agents ,MEDICINE ,GENETICS ,NEUROBLASTOMA ,GENETIC mutation ,SEQUENCE analysis ,MATHEMATICAL models ,ACCURACY ,DRUG resistance ,CANCER patients ,RISK assessment ,SURVIVAL rate ,MEDICAL protocols ,THEORY ,CYCLOPHOSPHAMIDE ,GENOTYPES ,BODY fluid examination ,RARE diseases ,ALGORITHMS ,VINCRISTINE ,PHYSIOLOGY - Abstract
Simple Summary: Neuroblastoma is a rare type of cancer that usually affects children. The high-risk patients' expected survival rate is less than 50%. One reason is the lack of precision in the standard treatment protocol: a one-size-fits-all multi-modal therapy. The study presented in this paper was designed to address this deficit by optimising the use of two chemotherapeutic agents—vincristine and cyclophosphamide—during induction chemotherapy—the part of the protocol that shrinks the primary tumour before surgical removal. We combined a mathematical model and an optimisation algorithm to identify the best chemotherapy schedules for a cohort of virtual patients with different initial tumour compositions. Our results reveal novel strategies to exploit a pair of drugs with different levels of efficacy, provide a platform on which to individualise induction chemotherapy, and lay the foundation for a personalised therapy that leverages targeted therapies, multi-region sequencing, liquid biopsies, and modern computational methods to improve today's multi-modal therapy. Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly heterogeneous outcomes in different tumours. In this study, we formulated a mathematical model comprising ordinary differential equations. The equations describe the clonal evolution within a neuroblastoma tumour being treated with vincristine and cyclophosphamide, which are used in the rapid COJEC regimen, including genetically conferred and phenotypic drug resistance. The equations also describe the agents' pharmacokinetics. We devised an optimisation algorithm to find the best chemotherapy schedules for tumours with different pre-treatment clonal compositions. The optimised chemotherapy schedules exploit the cytotoxic difference between the two drugs and intra-tumoural clonal competition to shrink the tumours as much as possible during induction chemotherapy and before surgical removal. They indicate that induction chemotherapy can be improved by finding and using personalised schedules. More broadly, we propose that the overall multi-modal therapy can be enhanced by employing targeted therapies against the mutations and oncogenic pathways enriched and activated by the chemotherapeutic agents. To translate the proposed personalised multi-modal therapy into clinical use, patient-specific model calibration and treatment optimisation are necessary. This entails a decision support system informed by emerging medical technologies such as multi-region sequencing and liquid biopsies. The results and tools presented in this paper could be the foundation of this decision support system. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images.
- Author
-
Veiga-Canuto, Diana, Cerdà-Alberich, Leonor, Jiménez-Pastor, Ana, Carot Sierra, José Miguel, Gomis-Maya, Armando, Sangüesa-Nebot, Cinta, Fernández-Patón, Matías, Martínez de las Heras, Blanca, Taschner-Mandl, Sabine, Düster, Vanessa, Pötschger, Ulrike, Simon, Thorsten, Neri, Emanuele, Alberich-Bayarri, Ángel, Cañete, Adela, Hero, Barbara, Ladenstein, Ruth, and Martí-Bonmatí, Luis
- Subjects
DEEP learning ,NEUROBLASTOMA ,SEQUENCE analysis ,RESEARCH methodology ,MACHINE learning ,MAGNETIC resonance imaging ,TUMOR classification ,DESCRIPTIVE statistics ,RESEARCH funding ,ALGORITHMS ,TUMOR grading ,LONGITUDINAL method - Abstract
Simple Summary: Tumor segmentation is a key step in oncologic imaging processing. We have recently developed a model to detect and segment neuroblastic tumors on MR images based on deep learning architecture nnU-Net. In this work, we performed an independent validation of the automatic segmentation tool with a large heterogeneous dataset. We reviewed the automatic segmentations and manually edited them when necessary. We were able to show that the automatic network was able to locate and segment the primary tumor on the T2 weighted images in the majority of cases, with an extremely high agreement between the automatic tool and the manually edited masks. The time needed for manual adjustment was very low. Objectives. To externally validate and assess the accuracy of a previously trained fully automatic nnU-Net CNN algorithm to identify and segment primary neuroblastoma tumors in MR images in a large children cohort. Methods. An international multicenter, multivendor imaging repository of patients with neuroblastic tumors was used to validate the performance of a trained Machine Learning (ML) tool to identify and delineate primary neuroblastoma tumors. The dataset was heterogeneous and completely independent from the one used to train and tune the model, consisting of 300 children with neuroblastic tumors having 535 MR T2-weighted sequences (486 sequences at diagnosis and 49 after finalization of the first phase of chemotherapy). The automatic segmentation algorithm was based on a nnU-Net architecture developed within the PRIMAGE project. For comparison, the segmentation masks were manually edited by an expert radiologist, and the time for the manual editing was recorded. Different overlaps and spatial metrics were calculated to compare both masks. Results. The median Dice Similarity Coefficient (DSC) was high 0.997; 0.944–1.000 (median; Q1–Q3). In 18 MR sequences (6%), the net was not able neither to identify nor segment the tumor. No differences were found regarding the MR magnetic field, type of T2 sequence, or tumor location. No significant differences in the performance of the net were found in patients with an MR performed after chemotherapy. The time for visual inspection of the generated masks was 7.9 ± 7.5 (mean ± Standard Deviation (SD)) seconds. Those cases where manual editing was needed (136 masks) required 124 ± 120 s. Conclusions. The automatic CNN was able to locate and segment the primary tumor on the T2-weighted images in 94% of cases. There was an extremely high agreement between the automatic tool and the manually edited masks. This is the first study to validate an automatic segmentation model for neuroblastic tumor identification and segmentation with body MR images. The semi-automatic approach with minor manual editing of the deep learning segmentation increases the radiologist's confidence in the solution with a minor workload for the radiologist. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Human repair‐related Schwann cells adopt functions of antigen‐presenting cells in vitro.
- Author
-
Berner, Jakob, Weiss, Tamara, Sorger, Helena, Rifatbegovic, Fikret, Kauer, Max, Windhager, Reinhard, Dohnal, Alexander, Ambros, Peter F., Ambros, Inge M., Boztug, Kaan, Steinberger, Peter, and Taschner‐Mandl, Sabine
- Published
- 2022
- Full Text
- View/download PDF
20. Comparative Multicentric Evaluation of Inter-Observer Variability in Manual and Automatic Segmentation of Neuroblastic Tumors in Magnetic Resonance Images.
- Author
-
Veiga-Canuto, Diana, Cerdà-Alberich, Leonor, Sangüesa Nebot, Cinta, Martínez de las Heras, Blanca, Pötschger, Ulrike, Gabelloni, Michela, Carot Sierra, José Miguel, Taschner-Mandl, Sabine, Düster, Vanessa, Cañete, Adela, Ladenstein, Ruth, Neri, Emanuele, and Martí-Bonmatí, Luis
- Subjects
DIGITAL image processing ,DEEP learning ,NEUROBLASTOMA ,MAGNETIC resonance imaging ,RETROSPECTIVE studies ,INTER-observer reliability ,COMPARATIVE studies ,AUTOMATION ,RECEIVER operating characteristic curves ,ALGORITHMS - Abstract
Simple Summary: Tumor segmentation is a key step in oncologic imaging processing and is a time-consuming process usually performed manually by radiologists. To facilitate it, there is growing interest in applying deep-learning segmentation algorithms. Thus, we explore the variability between two observers performing manual segmentation and use the state-of-the-art deep learning architecture nnU-Net to develop a model to detect and segment neuroblastic tumors on MR images. We were able to show that the variability between nnU-Net and manual segmentation is similar to the inter-observer variability in manual segmentation. Furthermore, we compared the time needed to manually segment the tumors from scratch with the time required for the automatic model to segment the same cases, with posterior human validation with manual adjustment when needed. Tumor segmentation is one of the key steps in imaging processing. The goals of this study were to assess the inter-observer variability in manual segmentation of neuroblastic tumors and to analyze whether the state-of-the-art deep learning architecture nnU-Net can provide a robust solution to detect and segment tumors on MR images. A retrospective multicenter study of 132 patients with neuroblastic tumors was performed. Dice Similarity Coefficient (DSC) and Area Under the Receiver Operating Characteristic Curve (AUC ROC) were used to compare segmentation sets. Two more metrics were elaborated to understand the direction of the errors: the modified version of False Positive (FPRm) and False Negative (FNR) rates. Two radiologists manually segmented 46 tumors and a comparative study was performed. nnU-Net was trained-tuned with 106 cases divided into five balanced folds to perform cross-validation. The five resulting models were used as an ensemble solution to measure training (n = 106) and validation (n = 26) performance, independently. The time needed by the model to automatically segment 20 cases was compared to the time required for manual segmentation. The median DSC for manual segmentation sets was 0.969 (±0.032 IQR). The median DSC for the automatic tool was 0.965 (±0.018 IQR). The automatic segmentation model achieved a better performance regarding the FPRm. MR images segmentation variability is similar between radiologists and nnU-Net. Time leverage when using the automatic model with posterior visual validation and manual adjustment corresponds to 92.8%. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. In preprints: recapitulation of development and wound healing shapes the spatial organization of glioblastoma.
- Author
-
Kameneva, Polina and Taschner-Mandl, Sabine
- Subjects
- *
GLIOBLASTOMA multiforme , *PREPRINTS , *HEALING , *ORGANIZATION - Published
- 2024
- Full Text
- View/download PDF
22. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.
- Author
-
van Gerven, Michael R., Bozsaky, Eva, Matser, Yvette A. H., Vosseberg, Julian, Taschner‐Mandl, Sabine, Koster, Jan, Tytgat, Godelieve A. M., Molenaar, Jan J., and van den Boogaard, Marlinde
- Abstract
Neuroblastoma is the most common extracranial solid tumor in children. The chromatin remodeler ATRX is frequently mutated in high‐risk patients with a poor prognosis. Although many studies have reported ATRX aberrations and the associated clinical characteristics in neuroblastoma, a comprehensive overview is currently lacking. In this study, we extensively characterize the mutational spectrum of ATRX aberrations in neuroblastoma tumors reported in previous studies and present an overview of patient and tumor characteristics. We collected the data of a total of 127 neuroblastoma patients and three cell lines with ATRX aberrations originating from 20 papers. We subdivide the ATRX aberrations into nonsense, missense, and multiexon deletions (MEDs) and show that 68% of them are MEDs. Of these MEDs, 75% are predicted to be in‐frame. Furthermore, we identify a missense mutational hotspot region in the helicase domain. We also confirm that all three ATRX mutation types are more often identified in patients diagnosed at an older age, but still approximately 40% of the patients are aged 5 years or younger at diagnosis. Surprisingly, we found that 11q deletions are enriched in neuroblastomas with ATRX deletions compared to a reference cohort, but not in neuroblastomas with ATRX point mutations. Taken together, our data emphasizes a distinct ATRX mutation spectrum in neuroblastoma, which should be considered when studying molecular phenotypes and therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation.
- Author
-
Kromp, Florian, Fischer, Lukas, Bozsaky, Eva, Ambros, Inge M., Dorr, Wolfgang, Beiske, Klaus, Ambros, Peter F., Hanbury, Allan, and Taschner-Mandl, Sabine
- Subjects
DEEP learning ,IMAGE segmentation ,IMMUNOFLUORESCENCE ,CONVOLUTIONAL neural networks ,COMPUTER architecture - Abstract
Separating and labeling each nuclear instance (instance-aware segmentation) is the key challenge in nuclear image segmentation. Deep Convolutional Neural Networks have been demonstrated to solve nuclear image segmentation tasks across different imaging modalities, but a systematic comparison on complex immunofluorescence images has not been performed. Deep learning based segmentation requires annotated datasets for training, but annotated fluorescence nuclear image datasets are rare and of limited size and complexity. In this work, we evaluate and compare the segmentation effectiveness of multiple deep learning architectures (U-Net, U-Net ResNet, Cellpose, Mask R-CNN, KG instance segmentation) and two conventional algorithms (Iterative h-min based watershed, Attributed relational graphs) on complex fluorescence nuclear images of various types. We propose and evaluate a novel strategy to create artificial images to extend the training set. Results show that instance-aware segmentation architectures and Cellpose outperform the U-Net architectures and conventional methods on complex images in terms of F1 scores, while the U-Net architectures achieve overall higher mean Dice scores. Training with additional artificially generated images improves recall and F1 scores for complex images, thereby leading to top F1 scores for three out of five sample preparation types. Mask R-CNN trained on artificial images achieves the overall highest F1 score on complex images of similar conditions to the training set images while Cellpose achieves the overall highest F1 score on complex images of new imaging conditions. We provide quantitative results demonstrating that images annotated by under-graduates are sufficient for training instance-aware segmentation architectures to efficiently segment complex fluorescence nuclear images. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.
- Author
-
Byrgazov, Konstantin, Anderson, Claes, Salzer, Benjamin, Bozsaky, Eva, Larsson, Rolf, Gullbo, Joachim, Lehner, Manfred, Lehmann, Fredrik, Slipicevic, Ana, Kager, Leo, Fryknäs, Mårten, and Taschner-Mandl, Sabine
- Abstract
Background: Low survival rates in metastatic high-grade osteosarcoma (HGOS) have remained stagnant for the last three decades. This study aims to investigate the role of aminopeptidase N (ANPEP) in HGOS progression and its targeting with a novel lipophilic peptidase-enhanced cytotoxic compound melphalan flufenamide (melflufen) in HGOS. Methods: Meta-analysis of publicly available gene expression datasets was performed to determine the impact of ANPEP gene expression on metastasis-free survival of HGOS patients. The efficacy of standard-of-care anti-neoplastic drugs and a lipophilic peptidase-enhanced cytotoxic conjugate melflufen was investigated in patient-derived HGOS ex vivo models and cell lines. The kinetics of apoptosis and necrosis induced by melflufen and doxorubicin were compared. Anti-neoplastic effects of melflufen were investigated in vivo. Results: Elevated ANPEP expression in diagnostic biopsies of HGOS patients was found to significantly reduce metastasis-free survival. In drug sensitivity assays, melflufen has shown an anti-proliferative effect in HGOS ex vivo samples and cell lines, including those resistant to methotrexate, etoposide, doxorubicin, and PARP inhibitors. Further, HGOS cells treated with melflufen displayed a rapid induction of apoptosis and this sensitivity correlated with high expression of ANPEP. In combination treatments, melflufen demonstrated synergy with doxorubicin in killing HGOS cells. Finally, Melflufen displayed anti-tumor growth and anti-metastatic effects in vivo. Conclusion: This study may pave the way for use of melflufen as an adjuvant to doxorubicin in improving the therapeutic efficacy for the treatment of metastatic HGOS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data.
- Author
-
Eghbal-Zadeh, Hamid, Fischer, Lukas, Popitsch, Niko, Kromp, Florian, Taschner-Mandl, Sabine, Gerber, Teresa, Bozsaky, Eva, Ambros, Peter F., Ambros, Inge M., Widmer, Gerhard, and Moser, Bernhard A.
- Published
- 2019
- Full Text
- View/download PDF
26. High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.
- Author
-
Ladenstein, Ruth Lydia, Poetschger, Ulrike, Valteau Couanet, Dominique, Ash, Shifra, Beck Popovic, Maja, Balwierz, Walentyna, Boterberg, Tom, Chan, Godfrey Chi-Fung, Elliott, Martin, Kogner, Per, Lode, Holger N., Laureys, Genevieve, Luksch, Roberto, Malis, Josef, Owens, Cormac, Papadakis, Vassilios, Sarnacki, Sabine, Taschner-Mandl, Sabine, Schleiermacher, Gudrun, and Canete, Adela
- Published
- 2023
- Full Text
- View/download PDF
27. Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype.
- Author
-
Weiss, Tamara, Taschner‐Mandl, Sabine, Bileck, Andrea, Slany, Astrid, Kromp, Florian, Rifatbegovic, Fikret, Frech, Christian, Windhager, Reinhard, Kitzinger, Hugo, Tzou, Chieh‐Han, Ambros, Peter F., Gerner, Christopher, and Ambros, Inge M.
- Published
- 2016
- Full Text
- View/download PDF
28. VP2: Schwann Cells Regulate Neuronal Differentiation by Epidermal Growth Factor-Like Protein 8.
- Author
-
Weiss, Tamara, Taschner-Mandl, Sabine, Janker, Lukas, Bileck, Andrea, Rifatbegovic, Fikret, Kromp, Florian, Sorger, Helena, Kauer, Maximilian O., Frech, Christian, Windhager, Reinhard, Gerner, Christopher, Ambros, Peter F., and Ambros, Inge M.
- Published
- 2022
- Full Text
- View/download PDF
29. Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies—A Validation Study.
- Author
-
Rifatbegovic, Fikret, Abbasi, M. Reza, Taschner-Mandl, Sabine, Kauer, Maximilian, Weinhäusel, Andreas, Handgretinger, Rupert, and Ambros, Peter F.
- Subjects
NEUROBLASTOMA ,BONE marrow cancer ,METASTASIS ,GENE expression ,CANCER relapse ,POLYMERASE chain reaction ,THERAPEUTICS - Abstract
Background: Metastases in the bone marrow (BM) in form of disseminated tumor cells (DTCs) are frequent events at diagnosis and also at relapse in high-risk neuroblastoma patients. The frequently highly diluted occurrence of DTCs requires adequate enrichment strategies to enable their detailed characterization. However, to avoid methodical artifacts we tested whether pre-analytical processing steps—including transport duration, temperature and, importantly, tumor cell enrichment techniques—are confounding factors for gene expression analysis in DTCs. Methods: LAN-1 neuroblastoma cells were spiked into tumor free BM and/or peripheral blood and: i) kept at room temperature or at 4°C for 24, 48 and 72 hours; ii) frozen down at -80°C and thawed; iii) enriched via magnetic beads. The effect on the gene expression signature of LAN-1 cells was analyzed by qPCR arrays and gene expression microarrays. Results: Neither storage at –80°C in DMSO and subsequent thawing nor enrichment of spiked-in neuroblastoma cells changed the expression of the analyzed genes significantly. Whereas storage at 4°C altered the expression of analyzed genes (14.3%) only at the 72h-timepoint in comparison to the 0h-timepoint, storage at room temperature had a much more profound effect on gene expression by affecting 20% at 24h, 26% at 48h and 43% at 72h of the analyzed genes. Conclusion: Using neuroblastoma as a model, we show that tumor cell enrichment by magnetic bead separation has virtually no effect on gene expression in DTCs. However, transport time and temperature can influence the expression profile remarkably. Thus, the expression profile of routinely collected BM samples can be analyzed without concern as long as the transport conditions are monitored. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging.
- Author
-
Lazic, Daria, Kromp, Florian, Rifatbegovic, Fikret, Repiscak, Peter, Kirr, Michael, Mivalt, Filip, Halbritter, Florian, Bernkopf, Marie, Bileck, Andrea, Ussowicz, Marek, Ambros, Inge M., Ambros, Peter F., Gerner, Christopher, Ladenstein, Ruth, Ostalecki, Christian, and Taschner-Mandl, Sabine
- Subjects
NEUROBLASTOMA ,METASTASIS ,GENE expression profiling ,BONE marrow ,DATA mining - Abstract
Simple Summary: Bone marrow metastasis frequently occurs in patients with solid cancers and most often leads to poor outcome. Yet, the composition of bone marrow metastases, including tumor and surrounding cells, has so far not been characterized. Herein, we aimed to investigate the diversity of tumor and surrounding cells, i.e., the microenvironment, in bone marrow metastases, using the childhood tumor neuroblastoma as a model. To this end, we screened genome-wide datasets to define a panel of cell-specific markers for multiplex microscopy of metastatic bone marrow samples, and developed DeepFLEX, a computational pipeline for subsequent image analysis. Thereby, we identified 35,000 single cells covering metastasized tumor cells, and various types of developing immune and bone marrow cells. In parallel, we analyzed the transcriptome, i.e., all genes that are expressed as mRNA, of 38 patients with and without bone marrow metastasis. We found vast tumor cell diversity and identified a marker protein, FAIM2, which can help to identify a broader range of tumor cell variants. In addition we showed that tumor cell metastasis in the bone marrow is associated with an immune response resembling inflammation, and the presence of cells that can repress an immune attack against cancer cells. Our study suggests that metastatic tumor cells are shaping the bone marrow microenvironment and builds the basis to further investigate its clinical relevance. While the bone marrow attracts tumor cells in many solid cancers leading to poor outcome in affected patients, comprehensive analyses of bone marrow metastases have not been performed on a single-cell level. We here set out to capture tumor heterogeneity and unravel microenvironmental changes in neuroblastoma, a solid cancer with bone marrow involvement. To this end, we employed a multi-omics data mining approach to define a multiplex imaging panel and developed DeepFLEX, a pipeline for subsequent multiplex image analysis, whereby we constructed a single-cell atlas of over 35,000 disseminated tumor cells (DTCs) and cells of their microenvironment in the metastatic bone marrow niche. Further, we independently profiled the transcriptome of a cohort of 38 patients with and without bone marrow metastasis. Our results revealed vast diversity among DTCs and suggest that FAIM2 can act as a complementary marker to capture DTC heterogeneity. Importantly, we demonstrate that malignant bone marrow infiltration is associated with an inflammatory response and at the same time the presence of immuno-suppressive cell types, most prominently an immature neutrophil/granulocytic myeloid-derived suppressor-like cell type. The presented findings indicate that metastatic tumor cells shape the bone marrow microenvironment, warranting deeper investigations of spatio-temporal dynamics at the single-cell level and their clinical relevance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo.
- Author
-
Pascoal, Susana, Salzer, Benjamin, Scheuringer, Eva, Wenninger-Weinzierl, Andrea, Sturtzel, Caterina, Holter, Wolfgang, Taschner-Mandl, Sabine, Lehner, Manfred, and Distel, Martin
- Subjects
TUMOR treatment ,ANIMAL experimentation ,B cells ,CELL lines ,CELL receptors ,CELL motility ,FISHES ,IMMUNOTHERAPY ,T cells ,XENOGRAFTS ,EMBRYOS ,IN vivo studies - Abstract
Chimeric antigen receptor (CAR) T cells have proven to be a powerful cellular therapy for B cell malignancies. Massive efforts are now being undertaken to reproduce the high efficacy of CAR T cells in the treatment of other malignancies. Here, predictive preclinical model systems are important, and the current gold standard for preclinical evaluation of CAR T cells are mouse xenografts. However, mouse xenograft assays are expensive and slow. Therefore, an additional vertebrate in vivo assay would be beneficial to bridge the gap from in vitro to mouse xenografts. Here, we present a novel assay based on embryonic zebrafish xenografts to investigate CAR T cell-mediated killing of human cancer cells. Using a CD19-specific CAR and Nalm-6 leukemia cells, we show that live observation of killing of Nalm-6 cells by CAR T cells is possible in zebrafish embryos. Furthermore, we applied Fiji macros enabling automated quantification of Nalm-6 cells and CAR T cells over time. In conclusion, we provide a proof-of-principle study that embryonic zebrafish xenografts can be used to investigate CAR T cell-mediated killing of tumor cells. This assay is cost-effective, fast, and offers live imaging possibilities to directly investigate CAR T cell migration, engagement, and killing of effector cells. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
- Author
-
Veiga-Canuto D, Fernández-Patón M, Cerdà Alberich L, Jiménez Pastor A, Gomis Maya A, Carot Sierra JM, Sangüesa Nebot C, Martínez de Las Heras B, Pötschger U, Taschner-Mandl S, Neri E, Cañete A, Ladenstein R, Hero B, Alberich-Bayarri Á, and Martí-Bonmatí L
- Subjects
- Humans, Male, Female, Retrospective Studies, Reproducibility of Results, Child, Preschool, Child, Infant, Image Interpretation, Computer-Assisted methods, Radiomics, Neuroblastoma diagnostic imaging, Neuroblastoma pathology, Magnetic Resonance Imaging methods
- Abstract
Purpose To evaluate the reproducibility of radiomics features extracted from T2-weighted MR images in patients with neuroblastoma. Materials and Methods A retrospective study included 419 patients (mean age, 29 months ± 34 [SD]; 220 male, 199 female) with neuroblastic tumors diagnosed between 2002 and 2023, within the scope of the PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers (ie, PRIMAGE) project, involving 746 T2/T2*-weighted MRI sequences at diagnosis and/or after initial chemotherapy. Images underwent processing steps (denoising, inhomogeneity bias field correction, normalization, and resampling). Tumors were automatically segmented, and 107 shape, first-order, and second-order radiomics features were extracted, considered as the reference standard. Subsequently, the previous image processing settings were modified, and volumetric masks were applied. New radiomics features were extracted and compared with the reference standard. Reproducibility was assessed using the concordance correlation coefficient (CCC); intrasubject repeatability was measured using the coefficient of variation (CoV). Results When normalization was omitted, only 5% of the radiomics features demonstrated high reproducibility. Statistical analysis revealed significant changes in the normalization and resampling processes ( P < .001). Inhomogeneities removal had the least impact on radiomics (83% of parameters remained stable). Shape features remained stable after mask modifications, with a CCC greater than 0.90. Mask modifications were the most favorable changes for achieving high CCC values, with a radiomics features stability of 70%. Only 7% of second-order radiomics features showed an excellent CoV of less than 0.10. Conclusion Modifications in the T2-weighted MRI preparation process in patients with neuroblastoma resulted in changes in radiomics features, with normalization identified as the most influential factor for reproducibility. Inhomogeneities removal had the least impact on radiomics features. Keywords: Pediatrics, MR Imaging, Oncology, Radiomics, Reproducibility, Repeatability, Neuroblastic Tumors Supplemental material is available for this article. © RSNA, 2024 See also the commentary by Safdar and Galaria in this issue.
- Published
- 2024
- Full Text
- View/download PDF
33. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
- Author
-
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, and Mackall CL
- Subjects
- Animals, Cell Line, Tumor, Glypicans metabolism, Humans, Immunotherapy methods, Neuroblastoma pathology, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes drug effects, T-Lymphocytes immunology, Xenograft Model Antitumor Assays methods, Glypicans immunology, Immunotherapy, Adoptive, Neuroblastoma drug therapy, Receptors, Antigen, T-Cell metabolism
- Abstract
Pediatric cancers often mimic fetal tissues and express proteins normally silenced postnatally that could serve as immune targets. We developed T cells expressing chimeric antigen receptors (CARs) targeting glypican-2 (GPC2), a fetal antigen expressed on neuroblastoma (NB) and several other solid tumors. CARs engineered using standard designs control NBs with transgenic GPC2 overexpression, but not those expressing clinically relevant GPC2 site density (∼5,000 molecules/cell, range 1-6 × 10
3 ). Iterative engineering of transmembrane (TM) and co-stimulatory domains plus overexpression of c-Jun lowered the GPC2-CAR antigen density threshold, enabling potent and durable eradication of NBs expressing clinically relevant GPC2 antigen density, without toxicity. These studies highlight the critical interplay between CAR design and antigen density threshold, demonstrate potent efficacy and safety of a lead GPC2-CAR candidate suitable for clinical testing, and credential oncofetal antigens as a promising class of targets for CAR T cell therapy of solid tumors., Competing Interests: Declaration of interest C.L.M., S.H., J.M.M., K.R.B., R.G.M., D.S.D., and Z.Z. are co-inventors on patents related to this work. C.L.M. (and others) have multiple patents pertinent to CAR T cells. C.L.M. is a co-founder of Lyell Immunopharma and Syncopation Life Sciences, which develop CAR-based therapies, and consults for Lyell, NeoImmune Tech, Apricity, Nektar, and Immatics. K.R.B. and J.M.M. receive research funding from Tmunity for research on GPC2-directed immunotherapies. D.Z., Z.Z., D.S.D., J.M.M., and K.R.B. receive royalties from Tmunity for licensing of GPC2-related IP. R.G.M. and E.S. are consultants for and hold equity in Lyell Immunopharma. R.G.M. consults for GammaDelta Therapeutics, Aptorum Group, Zai Lab, and Illumina Radiopharmaceuticals and J.T. for Dorian Therapeutics. S.J.B. is an employee of BD Biosciences. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Arsenal Biosciences and 10× Genomics. K.R.P. is a co-founder and employee of Cartography Biosciences. H.Y.C. is a co-founder of Accent Therapeutics and Boundless Bio and is an advisor to 10× Genomics, Arsenal Bio, and Spring Discovery., (Copyright © 2021. Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
34. Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
- Author
-
Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, and Schleiermacher G
- Subjects
- Child, Preschool, Clinical Trials, Phase III as Topic, Europe, Female, Follow-Up Studies, Humans, Infant, Male, N-Myc Proto-Oncogene Protein genetics, Prognosis, Randomized Controlled Trials as Topic, Risk Factors, Survival Rate, Anaplastic Lymphoma Kinase genetics, Gene Amplification, Mutation Rate, Neuroblastoma genetics
- Abstract
Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact., Materials and Methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571)., Results: Genomic ALK amplification ( ALK a) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALK a was associated with a significantly poorer overall survival (OS) (5-year OS: ALK a [n = 41] 28% [95% CI, 15 to 42]; no- ALK a [n = 860] 51% [95% CI, 47 to 54], [ P < .001]), particularly in cases with metastatic disease. ALK mutations ( ALK m) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALK m and MNA ( P < .001). Among 571 cases with known ALK a and ALK m status, a statistically significant difference in OS was observed between cases with ALK a or clonal ALK m versus subclonal ALK m or no ALK alterations (5-year OS: ALK a [n = 19], 26% [95% CI, 10 to 47], clonal ALK m [n = 65] 33% [95% CI, 21 to 44], subclonal ALK m (n = 22) 48% [95% CI, 26 to 67], and no alteration [n = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALK a (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome., Conclusion: Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations., Competing Interests: Walentyna BalwierzHonoraria: Shire, Gilead Sciences, Novartis, AmgenConsulting or Advisory Role: Amgen, Novartis, Roche, TakedaTravel, Accommodations, Expenses: Jazz Pharmaceuticals, Shire, Roche, Servier Martin ElliottConsulting or Advisory Role: Bayer Dominique Valteau-CouanetConsulting or Advisory Role: EUSA PharmaResearch Funding: Orphelia PharmaPatents, Royalties, Other Intellectual Property: Royalties from Apeiron to SIOPENTravel, Accommodations, Expenses: EUSA Pharma, Jazz Pharmaceuticals Deborah A. TweddleHonoraria: Eusa PharmaTravel, Accommodations, Expenses: EUSA Pharma Ruth LadensteinHonoraria: Apeiron Biologics, Boehringer Ingelheim, EUSA PharmaConsulting or Advisory Role: Apeiron Biologics, Boehringer Ingelheim, EUSA PharmaResearch Funding: Apeiron Biologics, EUSA PharmaPatents, Royalties, Other Intellectual Property: Apeiron Biologics, EUSA PharmaExpert Testimony: Apeiron Biologics, EUSA PharmaTravel, Accommodations, Expenses: Apeiron Biologics, EUSA Pharma Gudrun SchleiermacherHonoraria: BMSResearch Funding: Bristol Myers Squibb, Pfizer, MSDavenir, RocheTravel, Accommodations, Expenses: RocheNo other potential conflicts of interest were reported.
- Published
- 2021
- Full Text
- View/download PDF
35. Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis.
- Author
-
Gerber T, Taschner-Mandl S, Saloberger-Sindhöringer L, Popitsch N, Heitzer E, Witt V, Geyeregger R, Hutter C, Schwentner R, Ambros IM, and Ambros PF
- Subjects
- Adolescent, Adult, Aged, Blood Donors, Edetic Acid chemistry, Feasibility Studies, Female, Heparin chemistry, Humans, Liquid Biopsy methods, Male, Middle Aged, Molecular Diagnostic Techniques methods, Phenotype, Temperature, Time Factors, Young Adult, Blood Specimen Collection methods, Circulating Tumor DNA genetics, Diagnostic Tests, Routine methods, Flow Cytometry methods, Genetic Testing methods, Leukocytes, Whole Genome Sequencing methods
- Abstract
Liquid biopsies as a minimally invasive approach have the potential to revolutionize molecular diagnostics. Yet, although protocols for sample handling and the isolation of circulating tumor DNA (ctDNA) are numerous, comprehensive guidelines for diagnostics and research considering all aspects of real-life multicenter clinical studies are currently not available. These include limitations in sample volume, transport, and blood collection tubes. We tested the impact of commonly used (EDTA and heparin) and specialized blood collection tubes and storage conditions on the yield and purity of cell-free DNA for the application in down-stream analysis. Moreover, we evaluated the feasibility of a combined workflow for ctDNA and tumor cell genomic testing and parallel flow cytometric analysis of leukocytes. For genomic analyses, EDTA tubes showed good results if stored for a maximum of 4 hours at room temperature or for up to 24 hours when stored at 4°C. Spike-in experiments revealed that EDTA tubes in combination with density gradient centrifugation allowed the parallel isolation of ctDNA, leukocytes, and low amounts of tumor cells (0.1%) and their immunophenotyping by flow cytometry and down-stream genomic analysis by whole genome sequencing. In conclusion, adhering to time and temperature limits allows the use of routine EDTA blood samples for liquid biopsy analyses. We further provide a workflow enabling the parallel analysis of cell-free and cellular features for disease monitoring and for clonal evolution studies., (Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
36. Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells.
- Author
-
Weiss T, Taschner-Mandl S, Ambros PF, and Ambros IM
- Subjects
- Cells, Cultured, Fibroblasts cytology, Fibroblasts metabolism, Fluorescent Antibody Technique, Humans, Cell Culture Techniques methods, Schwann Cells cytology, Schwann Cells metabolism
- Abstract
This chapter emphasizes detailed protocols for the effective establishment of highly enriched human Schwann cell cultures and their characterization via immunostaining. The Schwann cells are isolated from immediately dissociated fascicle tissue and expanded prior to purification. Two purification methods are described that use either fluorescence-activated cell sorting for the Schwann cell marker TNR16 (p75
NTR ) or a less-manipulative two-step enrichment exploiting the differential adhesion properties of Schwann cells and fibroblasts, which is especially useful for low Schwann cell numbers. In addition, a method to determine Schwann cell purity via stained cytospin slides is introduced. Together with an immunofluorescence staining procedure for the combined analysis of extra- and intracellular markers, this chapter provides a solid basis to study human primary Schwann cells.- Published
- 2018
- Full Text
- View/download PDF
37. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
- Author
-
Taschner-Mandl S, Schwarz M, Blaha J, Kauer M, Kromp F, Frank N, Rifatbegovic F, Weiss T, Ladenstein R, Hohenegger M, Ambros IM, and Ambros PF
- Subjects
- Animals, Apoptosis drug effects, Blotting, Western, Cell Cycle drug effects, Cell Proliferation drug effects, Female, Fluorescent Antibody Technique, Humans, In Vitro Techniques, Mice, Neuroblastoma genetics, Neuroblastoma pathology, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Cellular Senescence drug effects, Gene Amplification, N-Myc Proto-Oncogene Protein genetics, Neuroblastoma prevention & control, Topoisomerase I Inhibitors pharmacology, Topotecan pharmacology
- Abstract
Poor prognosis and frequent relapses are major challenges for patients with high-risk neuroblastoma (NB), especially when tumors show MYCN amplification. High-dose chemotherapy triggers apoptosis, necrosis and senescence, a cellular stress response leading to permanent proliferative arrest and a typical senescence-associated secretome (SASP). SASP components reinforce growth-arrest and act immune-stimulatory, while others are tumor-promoting. We evaluated whether metronomic, i.e. long-term, repetitive low-dose, drug treatment induces senescence in vitro and in vivo. And importantly, by using the secretome as a discriminator for beneficial versus adverse effects of senescence, drugs with a tumor-inhibiting SASP were identified.We demonstrate that metronomic application of chemotherapeutic drugs induces therapy-induced senescence, characterized by cell cycle arrest, p21(WAF/CIP1) up-regulation and DNA double-strand breaks selectively in MYCN-amplified NB. Low-dose topotecan (TPT) was identified as an inducer of a favorable SASP while lacking NFKB1/p50 activation. In contrast, Bromo-deoxy-uridine induced senescent NB-cells secret a tumor-promoting SASP in a NFKB1/p50-dependent manner. Importantly, TPT-treated senescent tumor cells act growth-inhibitory in a dose-dependent manner on non-senescent tumor cells and MYCN expression is significantly reduced in vitro and in vivo. Furthermore, in a mouse xenotransplant-model for MYCN-amplified NB metronomic TPT leads to senescence selectively in tumor cells, complete or partial remission, prolonged survival and a favorable SASP.This new mode-of-action of metronomic TPT treatment, i.e. promoting a tumor-inhibiting type of senescence in MYCN-amplified tumors, is clinically relevant as metronomic regimens are increasingly implemented in therapy protocols of various cancer entities and are considered as a feasible maintenance treatment option with moderate adverse event profiles.
- Published
- 2016
- Full Text
- View/download PDF
38. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
- Author
-
Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, Wen X, Zhang S, Shern JF, Yohe ME, Taschner-Mandl S, Shohet JM, Thomas CJ, Martin SE, Ambros PF, and Khan J
- Subjects
- Animals, Apoptosis physiology, Aurora Kinase B genetics, Aurora Kinase B metabolism, Cell Line, Tumor, Female, Gene Knockdown Techniques, High-Throughput Nucleotide Sequencing methods, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Molecular Targeted Therapy, Neuroblastoma genetics, Neuroblastoma metabolism, Protein Kinase Inhibitors pharmacology, RNA Interference, Small Molecule Libraries pharmacology, Xenograft Model Antitumor Assays, Aurora Kinase B antagonists & inhibitors, Neuroblastoma enzymology, Neuroblastoma therapy
- Abstract
Despite advances in multimodal treatment, neuroblastoma (NB) is often fatal for children with high-risk disease and many survivors need to cope with long-term side effects from high-dose chemotherapy and radiation. To identify new therapeutic targets, we performed an siRNA screen of the druggable genome combined with a small molecule screen of 465 compounds targeting 39 different mechanisms of actions in four NB cell lines. We identified 58 genes as targets, including AURKB, in at least one cell line. In the drug screen, aurora kinase inhibitors (nine molecules) and in particular the AURKB-selective compound, barasertib, were the most discriminatory with regard to sensitivity for MYCN-amplified cell lines. In an expanded panel of ten NB cell lines, those with MYCN-amplification and wild-type TP53 were the most sensitive to low nanomolar concentrations of barasertib. Inhibition of the AURKB kinase activity resulted in decreased phosphorylation of the known target, histone H3, and upregulation of TP53 in MYCN-amplified, TP53 wild-type cells. However, both wild-type and TP53 mutant MYCN-amplified cell lines arrested in G2/M phase upon AURKB inhibition. Additionally, barasertib induced endoreduplication and apoptosis. Treatment of MYCN-amplified/TP53 wild-type neuroblastoma xenografts resulted in profound growth inhibition and tumor regression. Therefore, aurora B kinase inhibition is highly effective in aggressive neuroblastoma and warrants further investigation in clinical trials.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.